Free Trial

Atyr PHARMA Q4 2024 Earnings Report

Atyr PHARMA logo
$2.62 -0.17 (-6.09%)
As of 04/4/2025 04:00 PM Eastern

Atyr PHARMA EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Atyr PHARMA Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.02 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atyr PHARMA Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Atyr PHARMA Earnings Headlines

aTyr Pharma to Participate in April Investor Conferences
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Atyr PHARMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atyr PHARMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atyr PHARMA and other key companies, straight to your email.

About Atyr PHARMA

Atyr PHARMA (NASDAQ:ATYR), Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View Atyr PHARMA Profile

More Earnings Resources from MarketBeat